Skip to main content

propranolol

Generic: PROPRANOLOL HYDROCHLORIDE·Brand: HEMANGEOL, Hemangeol, INDERAL, INDERAL LA, INNOPRAN XL, Inderal, InnoPran, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE INTENSOL

propranolol: 8 clinical trials tracked.

propranolol evidence translation

What we can confirm

8 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about propranolol, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 2 study sponsors
Clinical Trials (8)

Comparative Efficacy of Propranolol, Flunarizine, and Their Combination in Migraine Prophylaxis: An Open-label Parallel-arm Randomized Controlled Trial

NCT07655700·Phase 4
Not yet recruiting

Primary endpoint: Change in Monthly Migraine Days

InterventionalRandomizedopen177 targetStarted 2026-07Completion 2027-041 site · BangladeshChittagong Medical College

Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast Cancer

NCT05741164·Phase 2·GPCR
Not yet recruiting

Primary endpoint: Objective response

Interventionalopen37 targetStarted 2026-03Completion 2028-112 sites · United StatesEmory University

Randomized Controlled Trial of Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

NCT07091279·Phase 2
Recruiting

Primary endpoint: Incidence of safety concerns and side effects associated with high-dose propranolol, including changes in blood pressure, pulse, and occurrence of dysrhythmias.

InterventionalRandomizedquadruple60 targetStarted 2026-01Completion 2028-122 sites · United StatesJeremy Veenstra-vanderweele

A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study

NCT06972056·Phase 4
Recruiting

Primary endpoint: Treatment Responder (atogepant vs. topiramate; atogepant vs. propranolol)

InterventionalRandomizedopen1,335 targetStarted 2025-07Completion 2029-1236 sites · United StatesMayo Clinic

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

NCT06120140·Phase 2
Active, not recruiting

Primary endpoint: Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment

InterventionalRandomizedopen305 targetStarted 2024-02Completion 2032-0150 sites · Argentina, Brazil, China, United StatesJanssen Research & Development, LLC

Evaluation of the Efficacy and Safety of Low-Dose Propranolol Combined With Intralesional Bleomycin for Infantile Hemangioma: A Randomized Controlled Trial

Completed

Primary endpoint: Clinical Therapeutic Effect

InterventionalRandomizedsingle260 enrolledStarted 2024-01Completion 2025-011 site · ChinaWuhan Integrated Traditional Chinese and Western Medicine Hospital

A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

NCT05561751·Phase 2·GPCR
Completed

Primary endpoint: Proportion of patients that achieve >=2 x 10^6 CD34+ cells/kg in 2 leukapheresis sessions

InterventionalRandomizedopen30 enrolledStarted 2023-02Completion 2025-1010 sites · United StatesGPCR Therapeutics, Inc.

Effect of Prophylactic, Perioperative Propranolol on Peri- and Postoperative Complications in Patients With Post Traumatic Stress Disorder

NCT01555554·Phase 4
Terminated

Primary endpoint: ICU Length of Stay

InterventionalRandomizedquadruple59 targetStarted 2012-05Completion 2019-061 site · United StatesUniversity of California, San Francisco